XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Accrued Expenses | 9 Months Ended
--- | ---
Sep. 30, 2022
Payables and Accruals [Abstract] |
Accrued Expenses | Accrued Expenses Accrued expenses consisted of:
| September 30, |  | December 31, |
| 2022 |  | 2021 |
Accrued royalties under the Medytox/Allergan Settlement Agreements | $ | 7,936 |  |  | $ | 12,447 |  |
Accrued payroll and related benefits | 7,094 |  |  | 6,856 |  |
Accrued revenue contract liabilities | 10,188 |  |  | 7,934 |  |
Other accrued expenses | 4,665 |  |  | 2,756 |  |
| $ | 29,883 |  |  | $ | 29,993 |  |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration